In the new normal of COVID-19, the debate about immediately sequential bilateral cataract surgery has come back in the limelight.Is it necessary? Is it possible? Is it risk-benefit profitable? Do we have a real advantage in performing it? These are som…
Keratoconus Progression Measurements Often Miss the Target
Dr Christopher Rapuano comments on a recent study showing significant measurement variability of the Pentacam, and what it may mean for treating progression. Medscape Ophthalmology
武田提供Novavax和Moderna的COVID-19候选疫苗在日本的1/2期临床试验的最新信息
日本大阪–(BUSINESS WIRE)–(美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天宣布,Novavax的COVID-19候选疫苗(TAK-019)在日本的1/2期免疫原性和安全性研究完成首例受试者接种。本月早些时候,武田完成了Moderna的COVID-19候选疫苗(TAK-919)在日本的1/2期免疫原性和安全性研究入组。 武田全球疫苗业务部总裁Rajeev Venkayya, M.D.表示:“在大流行初期,我们决定与其他公司合作,发挥我们丰富的疫苗经…
武田提供Novavax和Moderna的COVID-19候選疫苗在日本的1/2期臨床試驗的最新資訊
日本大阪–(BUSINESS WIRE)–(美國商業資訊)–武田藥品工業株式會社(TSE:4502/NYSE:TAK)今天宣布,Novavax的COVID-19候選疫苗(TAK-019)在日本的1/2期免疫原性和安全性研究完成首例受試者接種。本月稍早,武田完成了Moderna的COVID-19候選疫苗(TAK-919)在日本的1/2期免疫原性和安全性研究入組。 武田全球疫苗業務部總裁Rajeev Venkayya, M.D.表示:「在大流行初期,我們決定與其他公司合作,發揮我們豐富的疫苗經驗和…
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …